Trillium Therapeutics Receives Prestigious National Award

Trillium Therapeutics Inc. ("TTI") (TSX:TR)(OTCQX:SCTPF), an immuno-oncology
company developing innovative therapies for the treatment of cancer, today
announced that it has been awarded BIOTECanada's 2014 Gold Leaf Award as Early
Stage Health Company of the Year.


"We are honored to receive this coveted national award," remarked Trillium's
Chairman, Dr. Calvin Stiller. "The company had a remarkable year in 2013,
culminating in an unprecedented capital raise from premier healthcare funds.
This was made possible because of the substantial progress we made in advancing
our innovative CD47 checkpoint inhibitor program towards the clinic. It is
gratifying to see these accomplishments recognized by the industry."


"Every single member of the Trillium team has worked very hard to achieve our
goals and we all feel rightfully proud of this award from BIOTECanada and our
peers," added Dr. Niclas Stiernholm, President and CEO. "With the outstanding
team that we are fortunate to have assembled, we are optimistic that the future
of our company is bright."


About Trillium Therapeutics:

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company has two premier preclinical
programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune
system. SIRPaFc is an antibody-like fusion protein that blocks the activity of
CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia
(AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive molecule that
is overexpressed by many hematopoietic and solid tumors. TTI's clinical stage
programs include tigecycline, which is being evaluated in a multi-centre Phase I
study in patients with AML and TTI-1612, which has been tested in a 28-patient
Phase I trial in interstitial cystitis ("IC") patients. For more information,
visit: www.trilliumtherapeutics.com


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect TTI's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in TTI's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, TTI undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX nor its Regulation Services Provider (as that term is defined in the
policies of the TSX) accepts responsibility for the adequacy or accuracy of this
release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
[phone]
[e-mail]
www.trilliumtherapeutics.com